Medical devices with biointerface

01Overview and value chain

Markers: [EC: MDR 2017/745 | OECD: Biotech-health | Regulator: FDA (USA), EMA (European Union), NMPA (China)]

Medical devices with biointerface engineering govern how a catheter, guidewire, stent or implant actually meets living tissue at the surface, rather than the device’s structural or electrical function itself. Formacoat launched HydroMark, its proprietary hydrophilic coating platform, at MD&M West in January 2026, positioning it as an independent alternative to OEMs and CMOs amid consolidation among coating suppliers, building on more than 25 years in medical device coating services. Biocoat continues to innovate with a non-PFAS lumen coating method and its HYDAK hydrophilic coating line for guidewires and peripheral vascular devices, responding to regulatory pressure to eliminate PFAS from medical surfaces. Integer Holdings closed its acquisition of Precision Coating in January 2025, adding proprietary GlideLine fluoropolymer coatings, MICRALOX anodic coatings and IonGuard technology to its portfolio, and showcased an expanded coatings and R&D capability spanning PTFE, hydrophilic, parylene and advanced surface-modification technologies at MD&M West 2026. Freudenberg Medical launched LUBRITEQ, a new high-performance hydrophilic coating solution, in February 2026. DSM Biomedical (dsm-firmenich Biomedical) entered a strategic innovation collaboration with China’s Peijia Medical in 2025 to develop polymer heart-valve materials using UHMWPE and thermoplastic polyurethane, and maintained an active EuroPCR 2026 presence. In China, Sino Medical Sciences Technology received NMPA registration for a new-generation drug-eluting coronary stent system in February 2026.

The key directions of medical devices with biointerface are:

1. Hydrophilic lubricious coatings (Hydrophilic Lubricious Coatings): low-friction surface treatments for catheters, guidewires and other intravascular devices, easing insertion and reducing tissue trauma — Formacoat’s HydroMark, Biocoat’s HYDAK, Freudenberg Medical’s LUBRITEQ.
2. Multi-modal surface coating platforms (Multi-Modal Surface Platforms): broad coating portfolios spanning PTFE, hydrophilic, parylene and anodic technologies, scaled through acquisition into full-service coating-as-a-service offerings — Integer Holdings.
3. Bioactive anticoagulant polymer coatings (Bioactive Polymer Coatings): biomaterial and coating chemistries engineered for anticoagulant, anti-inflammatory or pro-endothelialization function on implanted device surfaces — DSM Biomedical’s polymer heart-valve and vascular-stent coating work.
4. Drug-eluting stent coating systems (Drug-Eluting Stent Coatings): polymer coatings that deliver a therapeutic agent from a stent surface into the vessel wall — Sino Medical Sciences Technology’s NMPA-approved coronary system.

Sectoral value chain

[biointerface coating chemistry design] ──> [coating process development/qualification] ──> [regulatory clearance (FDA/MDR/NMPA)]
                                                    │
                                       (OEM device integration)
                                                    │
                                                    ▼
[portfolio/platform expansion] <─── [clinical deployment] <─────┘

Value chain levels

Cross-cutting technologies of the sector:

• Hydrophilic lubricity chemistry (Hydrophilic Lubricious Coatings): surface treatments that create a slippery, low-friction layer on intravascular devices, reducing insertion force and tissue trauma.
• Multi-technology coating platforms (Multi-Modal Surface Platforms): integrated fluoropolymer, hydrophilic, parylene and anodic coating capabilities offered as a single supplier platform.
• Bioactive/anticoagulant surface functionalization (Bioactive Polymer Coatings): coatings engineered to actively modulate the biological response — inhibiting clotting or inflammation — at the device-tissue interface.

02US

The US hosts the leading concentration of biointerface coating suppliers, spanning independent specialists and a large-scale contract manufacturer built through acquisition.

Formacoat, Biocoat, Integer Holdings, FDA

• Formacoat: launched HydroMark, its proprietary hydrophilic coating platform, at MD&M West in January 2026, positioning it as an independent alternative to OEMs and CMOs amid consolidation among coating suppliers, building on more than 25 years in medical device coating services.
• Biocoat: continues to innovate with a non-PFAS lumen coating method and its HYDAK hydrophilic coating line for guidewires and peripheral vascular devices, responding to regulatory pressure to eliminate PFAS from medical surfaces.
• Integer Holdings: closed its acquisition of Precision Coating in January 2025, adding proprietary GlideLine fluoropolymer coatings, MICRALOX anodic coatings and IonGuard technology, and showcased an expanded coatings and R&D capability spanning PTFE, hydrophilic, parylene and advanced surface-modification technologies at MD&M West 2026.
• FDA framework: biointerface coatings are reviewed as part of their host device’s FDA 510(k) or PMA submission, with biocompatibility and particulate testing as core requirements rather than a standalone coating clearance.

03CN

China’s confirmed biointerface activity centers on a drug-eluting coronary stent coating cleared by NMPA in 2026, alongside a cross-border materials collaboration with a European supplier.

Sino Medical Sciences Technology, NMPA

• Sino Medical Sciences Technology (Tianjin, China; 688108.SH): received NMPA registration for a new-generation drug-eluting coronary stent system in February 2026, developed based on international frontier research for percutaneous coronary intervention (PCI).
• Cross-border materials note: Peijia Medical Technology (Suzhou) signed a 2025 strategic innovation collaboration with DSM Biomedical to develop polymer heart-valve materials using UHMWPE and thermoplastic polyurethane — a Chinese device maker sourcing biointerface materials science from a European supplier rather than a purely domestic coating platform.
• NMPA pathway: drug-eluting and biointerface-coated devices register with NMPA as part of the host device’s medical-device registration, following China’s standard risk-classified device pathway.

04EU

Germany and the Netherlands anchor Europe’s biointerface capacity, spanning a newly launched hydrophilic coating platform and bioactive polymer materials science with an active cross-border commercial link into China.

Freudenberg Medical, DSM Biomedical, MDR

• Freudenberg Medical (Germany-headquartered Freudenberg Group; medical coatings unit operating from Beverly, Massachusetts): launched LUBRITEQ, a new high-performance hydrophilic coating solution, in February 2026, positioned as a CDMO partner uniting advanced chemistry, device engineering and customer-first partnerships.
• DSM Biomedical (Netherlands; part of dsm-firmenich): entered a strategic innovation collaboration with China’s Peijia Medical in 2025 to develop polymer heart-valve materials using UHMWPE and thermoplastic polyurethane, and maintained an active EuroPCR 2026 presence; independent academic research in 2026 on dual-peptide (TPS/DGEA) anticoagulant and pro-endothelialization vascular stent coatings reflects the broader bioactive-coating research direction DSM Biomedical’s materials feed into.
• MDR framework: biointerface coatings on devices sold in the EU require conformity assessment under the Medical Device Regulation (MDR 2017/745) as part of the coated device’s overall CE marking.

05Leading companies and research institutes

06Tech stack and innovations

The stack applies surface-engineering chemistry to govern how a device’s surface interacts with blood and tissue — lubricity, thromboresistance, drug elution — independent of the device’s own structural function.

1. Hydrophilic lubricious coating chemistry (Hydrophilic Lubricious Coatings):
   • Formacoat’s HydroMark, Biocoat’s HYDAK and Freudenberg Medical’s LUBRITEQ each reduce catheter/guidewire insertion friction, with Biocoat’s non-PFAS lumen method addressing tightening PFAS regulation.
2. Multi-technology coating platforms (Multi-Modal Surface Platforms):
   • Integer Holdings’ GlideLine fluoropolymer, MICRALOX anodic and IonGuard coatings, scaled through the Precision Coating acquisition into a full-service surface-modification offering spanning PTFE, hydrophilic and parylene technologies.
3. Bioactive anticoagulant polymer coatings (Bioactive Polymer Coatings):
   • DSM Biomedical’s UHMWPE/thermoplastic-polyurethane polymer heart-valve materials, developed with Peijia Medical, and the broader dual-peptide anticoagulant/pro-endothelialization vascular stent coating research direction its materials feed into.
4. Drug-eluting stent coating systems (Drug-Eluting Stent Coatings):
   • Sino Medical Sciences Technology’s NMPA-approved drug-eluting coronary stent coating, developed for percutaneous coronary intervention.

07Value chains and production pipelines

Industrial pipeline of a biointerface-coated medical device (FDA 510(k)/PMA / EU MDR 2017/745 / NMPA)

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Coating chemistry      │ ───> │ 2. Process development/   │
│    design                    │      │    qualification            │
└───────────────────────────┘      └───────────────────────────┘
                                                   │
                                                   ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. OEM device              │ <─── │ 3. Regulatory clearance  │
│    integration               │      │                           │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Clinical deployment    │ ───> │ 6. Portfolio/platform     │
│                              │      │    expansion                │
└───────────────────────────┘      └───────────────────────────┘

Stage 1: Coating chemistry design

A hydrophilic, anticoagulant or drug-eluting surface chemistry is engineered for a specific device-tissue interface function, as with Formacoat’s HydroMark, Biocoat’s HYDAK or DSM Biomedical’s polymer heart-valve materials.

Stage 2: Process development and qualification

The coating application process is developed and validated for consistent, low-particulate performance, the specialty Integer Holdings scaled through five coating-focused acquisitions since 2006 including the 2025 Precision Coating deal.

Stage 3: Regulatory clearance

The coated device clears FDA 510(k)/PMA, EU MDR conformity assessment, or NMPA registration as part of its host device’s approval, as with Sino Medical Sciences Technology’s February 2026 NMPA-cleared drug-eluting stent system.

Stage 4: OEM device integration

Device manufacturers adopt the coating platform into their catheter, guidewire, stent or implant product line, the commercial model behind Formacoat’s positioning as an independent coating alternative amid supplier consolidation.

Stage 5: Clinical deployment

The coated device is used in vascular access, cardiology or other procedures, generating the performance and biocompatibility evidence behind platforms like Freudenberg Medical’s LUBRITEQ.

Stage 6: Portfolio and platform expansion

Coating suppliers expand technology breadth via new platform launches or acquisition to meet OEM demand for alternatives amid supplier consolidation, the pattern behind both Freudenberg Medical’s LUBRITEQ launch and Integer Holdings’ Precision Coating acquisition and expanded MD&M West 2026 showcase.